As the global pharmaceutical industry continues to restructure and regional cooperation deepens, Asia, particularly South Korea, is gradually becoming an important growth pole for biopharmaceuticals and health technology. CPHI Korea 2025, which will be held in August 2025, is not only a regional exhibition but also an important window for observing pharmaceutical innovation trends in Asia.
Date and opening hours:
August 26: 10:00 - 17:00
August 27: 10:00 - 17:00
August 28: 10:00 - 16:00
Venue:
COEX Convention Center, Seoul, South Korea
Official link:
https://www.cphi.com/korea/en/home.html
Why is this exhibition worth paying attention to?
1.South Korea's pharmaceutical policy continues to tilt toward “innovation and internationalization.” In recent years, South Korea has released the National Biopharmaceutical R&D Plan (2023–2028), proposing that the government and enterprises will jointly invest more than 10 billion US dollars in biopharmaceutical R&D. On April 2, 2025, the National Assembly of South Korea passed the Synthetic Biology Promotion Act, aiming to enhance its global position in biomanufacturing and related technology development. These policies all reflect South Korea's pharmaceutical policy trend toward innovation, while actively carrying out international cooperation. Global biopharmaceutical CDMO companies such as Samsung Biologics have participated, which aligns with the global pharmaceutical policy and development trends that CPHI focuses on. With the support and promotion of the South Korean government, the development of biopharmaceuticals, API localization, and international cooperation has accelerated, attracting a large number of CDMO and innovative pharmaceutical companies to settle.
2.East Asian buyers are concentrated, and supply chain cooperation demands are growing. This exhibition in South Korea covers APIs, biologics, nutritional and health ingredients, and CDMO services, and is expected to attract buyers and R&D institutions from countries such as South Korea, China, Japan, and Southeast Asia.
3.the natural ingredients and nutritional health sectors continue to expand. As part of the joint exhibition CPHI Hi Korea, fields such as natural ingredients and food additives have become new highlights. The boundary between health consumption and products derived from both food and medicine is becoming increasingly blurred, which also brings new opportunities to supply chain enterprises.
Our observation perspective:
As the pharmaceutical industry moves toward higher standards of transparency and global compliance, achieving integrated connection from raw materials to R&D to services will become a key to the competitiveness of supply chain enterprises. Even without exhibiting, understanding, paying attention to, and participating in regional industry trend discussions will also help enterprises gain more cooperation and orders in the future.